TACSTD2 and posterior cortical atrophy: Treating DKO with control or with a EZH2 inhibitor and using previously published PCa scRNAseq datasets (5, 34, 42, 43) to annotate cell identity, we found that vehicle treated DKO tumors predominately consist of L2/L2.1 progenitor like cells (Psca+/Krt4+/Tacstd2+) with smaller subsets of L1/L1.1/L1.2 intermediate/differentiated luminal cell types, and luminal-basal cell populations.